Share Twitter LinkedIn Facebook Email Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the trial Checkmate 142 Nivolumab & Ipilimumab and how it has shown a 55% Response Rate in MSI High patients. Recorded at ASCO GI 2018.
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read